![Robert Brenner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Robert Brenner
Directeur Technique/Scientifique/R&D chez
VERA THERAPEUTICS, INC.
Fortune : 241 643 $ au 31/05/2026
Profil
Robert M.
Brenner is Chief Medical Officer at Vera Therapeutics, Inc. since 2023.
Formerly, Dr. Brenner was President & Chief Executive Officer at AlloCure, Inc. in 2010; Executive Director-Nephrology Medical Affairs at Amgen, Inc. from 1999 to 2008; Senior Vice President-Medical Affairs at AMAG Pharmaceuticals, Inc. from 2008 to 2010; Chief Medical Officer at Orionis Biosciences, Inc. from 2015 to 2018; and Executive VP-Research & Development at Codiak BioSciences, Inc. from 2018 to 2019.
Education includes undergraduate studies at The Johns Hopkins University and a doctorate from Albert Einstein College of Medicine, Inc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 24/03/2026 | 6 803 ( 0,01 % ) | 241 643 $ | 31/05/2026 |
Postes actifs de Robert Brenner
| Sociétés | Poste | Début |
|---|---|---|
| VERA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 08/01/2023 |
Anciens postes connus de Robert Brenner
| Sociétés | Poste | Fin |
|---|---|---|
| CODIAK BIOSCIENCES | Directeur Technique/Scientifique/R&D | 01/03/2019 |
Orionis Biosciences, Inc.
 Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Offers protein interaction platform with direct applications in the discovery of new therapeutics | Directeur Technique/Scientifique/R&D | 01/09/2018 |
| AMAG PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 04/06/2010 |
| AMGEN INC. | Corporate Officer/Principal | 01/05/2008 |
AlloCure, Inc.
 AlloCure, Inc. BiotechnologyHealth Technology Develops cell therapies for the treatment of kidney diseases, organ transplants and multi-organ injuries | Directeur Général | 28/12/2010 |
Formation de Robert Brenner
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
83
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
The Johns Hopkins University
 The Johns Hopkins University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AMAG Pharmaceuticals, Inc.
 AMAG Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
AlloCure, Inc.
AlloCure, Inc. BiotechnologyHealth Technology Develops cell therapies for the treatment of kidney diseases, organ transplants and multi-organ injuries | Health Technology |
Albert Einstein College of Medicine, Inc.
 Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Orionis Biosciences, Inc.
Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Offers protein interaction platform with direct applications in the discovery of new therapeutics | Technology Services |
Codiak BioSciences, Inc.
 Codiak BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops exosome based therapeutics | Health Technology |
Vera Therapeutics, Inc.
 Vera Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company, which focuses on development and treatments for immunological & inflammatory diseases | Health Technology |
Choisissez Zonebourse 
